Related Experiment Video
Updated: May 18, 2026
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Update on disseminated intravascular coagulation: when to consider it, when to expect it, when to treat it
Alan G Ralph1, Benjamin M Brainard
1Department of Small Animal Clinical Sciences, College of Veterinary Medicine, East Lansing, MI 48824, USA. ralphal@cvm.msu.edu
Insights
Disseminated intravascular coagulation (DIC) is a complex condition with varied signs, often stemming from underlying issues like infection. Understanding DIC
Area of Science:
- Veterinary Internal Medicine
- Hematology
- Critical Care Medicine
Background:
- Disseminated intravascular coagulation (DIC) presents a spectrum of clinical manifestations, from excessive clotting to severe bleeding, often occurring simultaneously.
- DIC is invariably secondary to an underlying condition, frequently associated with systemic inflammation or infection.
- Pathogenesis involves endothelial dysfunction and dysregulation of procoagulant, anticoagulant, and fibrinolytic factors, unified by excessive thrombin generation.
Purpose of the Study:
- To elucidate the complex pathophysiology of Disseminated Intravascular Coagulation (DIC).
- To address the diagnostic challenges and therapeutic considerations for DIC, particularly in veterinary patients.
- To highlight the importance of understanding underlying pathology for optimizing patient outcomes.
Main Methods:
- Review of existing literature on DIC pathophysiology, clinical presentation, and diagnostic criteria.
- Analysis of hematologic changes, including platelet count and activated partial thromboplastin time (aPTT), for DIC recognition.
- Discussion of therapeutic strategies based on underlying disease processes.
Main Results:
- DIC is characterized by a continuum of phenotypes and varying severity (overt vs. non-overt).
- Diagnosis often relies on identifying significant hematologic alterations, such as thrombocytopenia and prolonged aPTT.
- Specific therapeutic benefits are challenging to definitively prove, necessitating a focus on managing the primary cause.
Conclusions:
- Effective management of DIC requires a thorough understanding of its complex pathophysiology and the patient's underlying condition.
- Despite diagnostic and therapeutic challenges, particularly in veterinary medicine due to interspecies variability, favorable outcomes are achievable.
- Optimized care, involving a collaborative veterinary team and committed owners, is crucial for improving prognosis in DIC patients.
Abstract:
Disseminated intravascular coagulation (DIC) spans a continuum in which clinical signs can range from a prothrombotic to a hemorrhagic phenotype, with some patients suffering from both concurrently. DIC is always caused by an underlying condition, with most cases linked to systemic inflammation or infection. Numerous factors contribute to the development of DIC, including aberrations in endothelial function, and altered levels of endogenous procoagulant, anticoagulant, and fibrinolytic factors. Excessive thrombin generation, or failure to localize thrombin production, is the unifying theme throughout this broad condition. DIC can be described as overt or nonovert, each with varying degrees of severity. The ability to concisely define and diagnose such a broad condition has proven challenging, especially in veterinary medicine, where interspecies differences result in phenotypic variability. In most patients, DIC is recognized when a patient experiences noteworthy hematologic changes, such as a drop in circulating platelet count in concert with a 20% to 30% prolongation in the activated partial thromboplastin time. Similar to diagnosing, proven benefits of any particular therapy are difficult to identify. Despite these difficulties, therapy can be optimized with an understanding of the underlying pathology(ies). With appropriate care and a committed owner/veterinary team, patients with DIC can have a favorable outcome.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:30Venous Thrombosis IV: Nursing Management
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:24Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.